Publications and Data Presentations

Interim Efficacy and Safety Data of Tazemetostat in Follicular Lymphoma and DLBCL from Ongoing Phase 2 Study

Jun, 2017

Preliminary Evidence of Molecular Predictors of Tazemetostat in NHL

Jun, 2017

Activity of EZH2 inhibitors as monotherapy and in combination with multiple myeloma therapies

Apr, 2017

Tazemetostat Phase 1 NHL Update at ASH Lymphoma

Jun, 2016 | ASH Lymphoma Biology

Tazemetostat Early Phase 2 NHL Study Findings Poster at ASH Lymphoma

Jun, 2016 | ASH Lymphoma Biology

Tazemetostat Early Phase 2 NHL Study Findings at ASH Lymphoma

Jun, 2016 | ASH Lymphoma Biology

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor Pinometostat (EPZ-5676) in Children with MLL-r Acute Leukemia: Safety, Exposure and Evidence of Target Inhibition

Dec, 2015

Identification of biomarkers and pathways associated with response to DOT1L inhibitor Pinometostat (EPZ-5676) in MLL-r leukemia

Nov, 2015

Pinometostat, EPZ-5676, Enhances the Anti-Proliferative Activity of MAP Kinase Pathway Inhibitors in Cell Lines Less Sensitive to DOT1L inhibition

Nov, 2015

EZH2 plays a critical role in B-cell maturation and in non-Hodgkin’s lymphoma: Interplay between EZH2 function and B-cell activation

Nov, 2015

CRISPR Pooled Screening Identifies Differential Dependencies on Epigenetic Pathways

Nov, 2015

A Medium-Throughput Single Cell CRISPR/Cas9 Assay to Assess Gene Essentiality

Nov, 2015

Identification of a First-In-Class PRMT5 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Dec, 2014 | ASH

Preclinical Evaluation of EZH2 Inhibitors in Models of Human Synovial Sarcoma

Oct, 2014

Small Molecule Control of Chromatin Remodeling

Sep, 2014 | Chemistry & Biology Review

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells

Jul, 2014 | Journal of Pharmacology and Experimental Therapeutics

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 Mutant Non-Hodgkin Lymphoma

Feb, 2014 | Molecular Cancer Therapeutics

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies in Preclinical Models

Dec, 2013 | ASH

Potent inhibition of DOT1L as a treatment for MLL-fusion leukemia

Aug, 2013 | Blood

Epizyme® announces that the “Nature Reprint Collection: Epigenetics” from Nature Publishing Group is now available online

May, 2013 | Nature Reprint Collection

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Mar, 2013 | PNAS

Chemogenetic analysis of human protein methyltransferases

Jun, 2011 | Chemical Biology & Drug Design

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

Oct, 2010 | PNAS

Epizyme Scientific Publications Reference

Jan, 2008